Literature DB >> 23382290

Clear cell renal cell carcinoma: discrimination from other renal cell carcinoma subtypes and oncocytoma at multiphasic multidetector CT.

Jonathan R Young1, Daniel Margolis, Steven Sauk, Allan J Pantuck, James Sayre, Steven S Raman.   

Abstract

PURPOSE: To determine whether enhancement at multiphasic multidetector computed tomography (CT) can help differentiate clear cell renal cell carcinoma (RCC) from oncocytoma, papillary RCC, and chromophobe RCC.
MATERIALS AND METHODS: With institutional review board approval for this HIPAA-compliant retrospective study, the pathology database was queried to derive a cohort of 298 cases of RCC and oncocytoma with preoperative multiphasic multidetector CT with as many as four phases (unenhanced, corticomedullary, nephrographic, and excretory). A total of 170 clear cell RCCs, 57 papillary RCCs, 49 oncocytomas, and 22 chromophobe RCCs were evaluated for multiphasic enhancement and compared by using t tests. Cutoff analysis was performed to determine optimal threshold levels to discriminate among the four groups.
RESULTS: Mean enhancement of clear cell RCCs and oncocytomas peaked in the corticomedullary phase; mean enhancement of papillary and chromophobe RCCs peaked in the nephrographic phase. Enhancement of clear cell RCCs was greater than that of oncocytomas in the corticomedullary (125 HU vs 106 HU, P = .045) and excretory (80 HU vs 67 HU, P = .034) phases. Enhancement of clear cell RCCs was greater than that of papillary RCCs in the corticomedullary (125 HU vs 54 HU, P < .001), nephrographic (103 HU vs 64 HU, P < .001), and excretory (80 HU vs 54 HU, P < .001) phases. Enhancement of clear cell RCCs was greater than that of chromophobe RCCs in the corticomedullary (125 HU vs 74 HU, P < .001) and excretory (80 HU vs 60 HU, P = .008) phases. Thresholding of enhancement helped to discriminate clear cell RCC from oncocytoma, papillary RCC, and chromophobe RCC with accuracies of 77% (83 of 108 cases), 85% (101 of 119 cases), and 84% (81 of 97 cases).
CONCLUSION: Enhancement at multiphasic multidetector CT, if prospectively validated, may assist in the discrimination of clear cell RCC from oncocytoma, papillary RCC, and chromophobe RCC. © RSNA, 2013.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23382290     DOI： 10.1148/radiol.13112617

Source DB:  PubMed          Journal:  Radiology        ISSN： 0033-8419            Impact factor:   11.105


  86 in total

Review 1.  Renal angiomyolipoma without visible fat: Can we make the diagnosis using CT and MRI?

Authors:  Robert S Lim; Trevor A Flood; Matthew D F McInnes; Luke T Lavallee; Nicola Schieda
Journal:  Eur Radiol       Date:  2017-08-04       Impact factor: 5.315

2.  MRI evaluation of small (<4cm) solid renal masses: multivariate modeling improves diagnostic accuracy for angiomyolipoma without visible fat compared to univariate analysis.

Authors:  Nicola Schieda; Marc Dilauro; Bardia Moosavi; Taryn Hodgdon; Gregory O Cron; Matthew D F McInnes; Trevor A Flood
Journal:  Eur Radiol       Date:  2015-10-20       Impact factor: 5.315

Review 3.  The role of renal biopsy in small renal masses.

Authors:  Rodolfo Burruni; Benoit Lhermitte; Yannick Cerantola; Thomas Tawadros; Jean-Yves Meuwly; Dominik Berthold; Patrice Jichlinski; Massimo Valerio
Journal:  Can Urol Assoc J       Date:  2016-01-14       Impact factor: 1.862

4.  Assessment of multiphasic contrast-enhanced MR textures in differentiating small renal mass subtypes.

Authors:  Uyen N Hoang; S Mojdeh Mirmomen; Osorio Meirelles; Jianhua Yao; Maria Merino; Adam Metwalli; W Marston Linehan; Ashkan A Malayeri
Journal:  Abdom Radiol (NY)       Date:  2018-12

5.  Effect of Stereotactic Body Radiotherapy on the Growth Kinetics and Enhancement Pattern of Primary Renal Tumors.

Authors:  Maryellen R M Sun; Alexander Brook; Michael F Powell; Krithica Kaliannan; Andrew A Wagner; Irving D Kaplan; Ivan Pedrosa
Journal:  AJR Am J Roentgenol       Date:  2016-03       Impact factor: 3.959

6.  Renal cell carcinomas with t(6;11) (p21;q12): presentation of two cases with computed tomography findings.

Authors:  YiJun Zhao; Jin Yao; Ni Chen; Hao Zeng; Wei Zhang
Journal:  Jpn J Radiol       Date:  2015-05-07       Impact factor: 2.374

Review 7.  Advances in medical imaging for the diagnosis and management of common genitourinary cancers.

Authors:  Mohammad H Bagheri; Mark A Ahlman; Liza Lindenberg; Baris Turkbey; Jeffrey Lin; Ali Cahid Civelek; Ashkan A Malayeri; Piyush K Agarwal; Peter L Choyke; Les R Folio; Andrea B Apolo
Journal:  Urol Oncol       Date:  2017-05-12       Impact factor: 3.498

Review 8.  Review of renal cell carcinoma and its common subtypes in radiology.

Authors:  Gavin Low; Guan Huang; Winnie Fu; Zaahir Moloo; Safwat Girgis
Journal:  World J Radiol       Date:  2016-05-28

Review 9.  Solid renal masses: what the numbers tell us.

Authors:  Stella K Kang; William C Huang; Pari V Pandharipande; Hersh Chandarana
Journal:  AJR Am J Roentgenol       Date:  2014-06       Impact factor: 3.959

10.  Society of Abdominal Radiology disease-focused panel on renal cell carcinoma: update on past, current, and future goals.

Authors:  Matthew S Davenport; Hersh Chandarana; Nicole E Curci; Ankur Doshi; Samuel D Kaffenberger; Ivan Pedrosa; Erick M Remer; Nicola Schieda; Atul B Shinagare; Andrew D Smith; Zhen J Wang; Shane A Wells; Stuart G Silverman
Journal:  Abdom Radiol (NY)       Date:  2018-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.